Diffuse Interstitial Lung Disease
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
- Interstitial lung diseases (ILDs) represent a diverse group of chronic progressive lung diseases associated with alveolar inflammation and/or potentially irreversible pulmonary fibrosis.
- >200 individual diseases may present with similar characteristics, making ILD difficult to classify.
- A classification scheme proposed by the American Thoracic Society and European Respiratory Society includes these subtypes:
- Known causes (environmental, occupational, or drug-associated disease)
- Systemic disorders (e.g., sarcoidosis, Wegener granulomatosis, collagen vascular disease)
- Rare lung diseases (e.g., pulmonary histiocytosis, lymphangioleiomyomatosis)
- Idiopathic interstitial pneumonias (IIPs)
- Based on clinical, radiologic, and histologic features, IIPs are further subclassified into the following diagnoses (1):
- Major IIPs, including idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated ILD (cryptogenic organizing pneumonia [COP], etc.)
- Rare IIPs
- Unclassifiable IIPs
- Classification of IIPs and relationships between the subtypes are difficult to classify due to mixed patterns of injury.
ILD in infants and children represents a heterogeneous group of respiratory disorders. Diseases result from a variety of processes involving genetic factors and inflammatory or fibrotic responses, and processes are distinct from those that cause ILD in adults (2). Some diseases result from developmental disorders and growth abnormalities in infancy (2). After common causes are excluded, referral of infants to a subspecialist is recommended (2).
- Exact incidence and prevalence are difficult to determine because of differences in case definitions and procedures used in diagnosis.
- Cited incidence of IPF in the United States: 16.3 to 17.4/100,000 and pediatric ILD 1.32/1 million
Cited prevalence of IPF in the United States: 42.7 to 63 cases/100,000 in the general population and pediatric ILD of 3.6/1 million
Etiology and Pathophysiology
- Alveolar inflammation may progress into irreversible fibrosis.
- Varying degrees of ventilatory dysfunction occur among the ILD subtypes.
- ILD associated with collagen vascular disease and systemic connective disorders can manifest involvement of skin, joints, muscular, and ocular systems.
- Some types of ILD are associated with specific exposures:
- Medications (amiodarone, antibiotics [especially nitrofurantoin], chemotherapy agents, gold, illicit drugs)
- Inorganic dusts (silicates, asbestos, talc, mica, coal dust, graphite)
- Organic dusts (moldy hay, inhalation of fungi, bacteria, animal proteins)
- Metals (tin, aluminum, cobalt, iron, barium)
- Gases, fumes, vapors, aerosols
Some subtypes of ILD may be associated with specific predisposing genes and environmental exposures; however, the role of genetic factors is unknown.
- Environmental or occupational exposure to inorganic or organic dusts
- 66–75% of patients with ILD have a history of smoking.
- Due to diversity of diseases, age is not a reliable predictor of pathology:
- Most patients with connective tissue disease-related pathology and inherited subtypes present between ages 20 and 40 years.
- Median age of patients with IPF is 66 years. Studies of clinical predictors of survival including age, ethnicity, and smoking status have been inconsistent.
Commonly Associated Conditions
Many systemic disorders and primary diseases are associated with ILD. A partial list includes the following:
- Collagen vascular disease
- Goodpasture syndrome
- Churg-Strauss syndrome
- Wegener granulomatosis